Delivery Order SPE2DB20D3103-SPE2DB22FN0K4
- Not listed
- The federal contract award is for the delivery of 4,568,494,683 vials of Levothyroxine 500 mcg to the Defense Logistics Agency (DLA), a defense agency. The contract is a Delivery Order with a Firm Fixed Price of $2,938.11 and an Ultimate Completion Date of June 10, 2025. The prime contractor is Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider based in Conshohocken, Pennsylvania. This delivery order is part of a larger Indefinite Delivery...
- This federal contract award, valued at $2,892.53, was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The award is for the delivery of levothyroxine 100 mcg vials, a medication used to treat hypothyroidism. The contract has a firm fixed price pricing type and an ultimate completion date of May 7, 2025. This award is not associated with a set-aside program, indicating open competition....
- This is a delivery order awarded to Amerisourcebergen Drug Corp, Corporate Office Division, by the Defense Logistics Agency (DLA) for the supply of 4,566,076 vials of 500 mcg Levothyroxine, a thyroid medication. The contract is a firm-fixed price arrangement with a ceiling value of $6,825.18 and an ultimate completion date of October 11, 2024. This award is not associated with a set-aside program. Amerisourcebergen is a major pharmaceutical distributor that has been awarded numerous federal...
- This is a delivery order contract awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is for the delivery of 4,567,806,709 vials of levothyroxine 200 mcg, a thyroid medication, with a ceiling value of $1,422.01. The contract has an ultimate completion date of April 7, 2025 and was awarded on April 4, 2025. It is a firm fixed price contract with no set-aside designation, indicating open...
- This is a federal contract award to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider, by the Defense Logistics Agency (DLA). The contract is for the delivery of Levothyroxine 100 mcg capsules, a prescription medication, with a ceiling value of $1,577.63 and a performance period extending to July 11, 2025. The contract is a Delivery Order under a larger Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, valued at...
- This federal contract award was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $3,225.95 Firm Fixed Price Delivery Order contract is for the supply of 4565057401 - Levothyroxine 50 MCG Tablet, 1000's. The contract has a period of performance through July 3, 2024. This award is associated with a larger Indefinite Delivery Contract (IDC) that Amerisourcebergen holds with the DLA Troop Support...
- This federal contract award is for the delivery of Levothyroxine 150mcg tablets to the Defense Logistics Agency (DLA) Troop Support Medical, a major supplier of pharmaceutical products and medical supplies to the U.S. Department of Defense (DoD) and Department of Veterans Affairs (VA). The contract, valued at $1,484.01, was awarded to Amerisourcebergen Drug Corp, a subsidiary of the parent company Cencora, Inc. This is a firm fixed-price delivery order contract with no set-aside designation,...
- This is a delivery order awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corporation, a major pharmaceutical distributor, for the supply of Levothyroxine 25 mcg capsules. The contract has a ceiling value of $1,230.19 and is set to run through August 5, 2024. This award is part of a larger Indefinite Delivery Contract (IDC) between AmerisourceBergen and the DLA Troop Support Medical, valued at up to $999,999,999 through December 2025, for delivering a comprehensive range...
- This federal contract award is a delivery order to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider, for the supply of LEVOTHYROXN 100MCG 30S medication. The contract has a firm fixed price of $2,899.56 and is funded by the Medical Supply Chain, a Defense agency. The award has a completion date of June 13, 2025 and is not designated as a set-aside. Amerisourcebergen Drug Corp holds a significant Indefinite Delivery Contract (IDC) with the...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on September 9, 2025, for the supply of Levothyroxine 200 mcg tablets in quantities of 1,000 units, with a ceiling value of $13,837.62. This is a firm fixed-price delivery order with no set-aside designation, meaning it was competitively awarded. The contract is scheduled for ultimate completion by September 10, 2025, and will be performed at AmerisourceBergen's corporate office location in Conshohocken,...
- SPE2DB20D3103Indefinite Delivery Contract
- SPE2DB20D3103-SPE2DB22FN0K4Delivery Order
This federal contract award was issued by the Defense Logistics Agency (DLA) to the prime contractor, Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is for the delivery of 4,556,604,296 vials of the medication Levothyroxine 100 MCG. The contract has a ceiling value of $3,583.33 and a period of performance through March 18, 2022. This is a delivery order contract with a firm fixed price pricing type. No set-aside designation is mentioned. Amerisourcebergen Drug Corp is a subsidiary of the parent company Cencora, Inc., which holds a significant $999,999,999.00 Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical through November 2026. This IDC serves as the primary vehicle for Amerisourcebergen to provide a wide range of pharmaceutical products and medical supplies to support military healthcare programs globally. The company also maintains a separate IDC with the Department of Justice Federal Bureau of Investigation, valued at up to $750,000 through May 2024, for similar medical products and prescription drugs.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $3.6k | 3/17/22 |